Evidence map›Paper›PMID 39530107›Full record

ArticleInternational journal of nanomedicine2024

pH-Responsive Charge-Reversal Smart Nanoparticles for Co-Delivery of Mitoxantrone and Copper Ions to Enhance Breast Cancer Chemo-Chemodynamic Combination Therapy.

Tao Tan, Weiyi Chang, Tian Long Wang, Wei Chen, Xiaobing Chen, Chunmiao Yang, Dongsheng Yang

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Stimuli-responsive bioengineered platforms for precision cancer therapy.Frontiers in bioengineering and biotechnology · 2026
    Review
  4. Engineering copper and copper-based materials for a post-antibiotic era.Frontiers in bioengineering and biotechnology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tao Tan *College of Life Science, Zhuhai College of Science and Technology, Zhuhai, 519041, People's Republic of China.
Weiyi Chang *College of Life Science, Zhuhai College of Science and Technology, Zhuhai, 519041, People's Republic of China.
Tian Long WangCollege of Life Science, Zhuhai College of Science and Technology, Zhuhai, 519041, People's Republic of China.
Wei ChenCollege of Life Science, Zhuhai College of Science and Technology, Zhuhai, 519041, People's Republic of China.
Xiaobing ChenCollege of Life Science, Zhuhai College of Science and Technology, Zhuhai, 519041, People's Republic of China.
Chunmiao YangCollege of Life Science, Zhuhai College of Science and Technology, Zhuhai, 519041, People's Republic of China.
Dongsheng YangCollege of Life Science, Zhuhai College of Science and Technology, Zhuhai, 519041, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The poor delivery and limited penetration of nanoparticles into breast cancer tumors remain essential challenges for effective anticancer therapy. This study aimed to design a promising nanoplatform with efficient tumor targeting and penetration capability for effective breast cancer therapy. Methods: A pH-sensitive mitoxantrone (MTO) and copper ion-loaded nanosystem functionalized with cyclic CRGDfK and r9 peptide (TPRN-CM) was rationally designed for chemo-chemodynamic combination therapy. TPRN-CM would be quiescent in blood circulation with the CRGDfK peptide on the surface of the nanoparticle to improve its targeting to the tumor. Then, the structure of TPRN-CM changes in the acidic tumor microenvironment, and the r9 peptide can be exposed to make a surface charge reversal to promote deep penetration in the tumor and facilitate their internalization by cancer cells, which was characterized using transmission electron microscopy, dynamic light scattering, flame atomic absorption, etc. The drug release behavior, anti-tumor effects in vivo and in vitro, and the biosafety of the nanoplatform were evaluated. Results: TPRN-CM exhibited remarkable capability to load MTO and Cu Conclusion: The constructed TPRN-CM nanoplatform integrated tumor targeting, tumor penetration, drug-responsive release, and chemo-chemodynamic combination therapy, thereby providing an intelligent drug delivery strategy to improve the efficacy of breast cancer treatment.

Indexed as

Breast NeoplasmsCopperMitoxantroneAnimalsAntineoplastic AgentsCell Line, TumorDrug LiberationFemaleHumansHydrogen-Ion ConcentrationMCF-7 CellsMiceMice, Inbred BALB CNanoparticle Drug Delivery SystemNanoparticlesOligopeptidesAntineoplastic AgentsCoppercysteinyl-arginyl-glutamyl-lysyl-alanylMitoxantroneNanoparticle Drug Delivery SystemOligopeptidesPeptides, Cyclicbreast cancercharge-reversalchemo-chemodynamic combination therapypenetrationpH-responsive

Identifiers

PMID39530107
PMCPMC11552415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.